Ob/Gyn Medical News about Ovarian Diseases Ovarian Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Current status of anti-angiogenic agents in the treatment of ovarian carcinoma
Clinical and Translational Oncology, 10/07/09

Sanchez–Munoz A et al. – During the last decade we have assisted in the development of new therapeutic strategies for the treatment of ovarian cancer, based on the best knowledge of molecular biology. One of the most promising strategies under investigation is antiangiogenic therapy. Other new therapeutic antiangiogenic strategies that include small–molecule tyrosine kinase inhibitors, antibodies neutralising the VEGF receptor (VEGFR) and soluble VEGFR hybrids (VEGF Trap) are being investigated with promising early results.

<< Previous
Blockage of ghrelin-induced prolactin secretion in women by...

Next >>
Prognostic indicators following ipsilateral tumor recurrence in...